This June, the Ovarian Cancer Research Foundation (OCRF) is calling for urgent support to part fund a researcher position within a promising research project. We have experienced an unprecedented number of high quality grant applications and need to raise an additional $45,000 to fund the most promising and innovative ovarian cancer research over the next financial year.

One of the most promising projects is the Active Ratio Test, conducted by the team at the Hudson Institute of Medical Research. This project is moving closer—through rigorous testing and prospective trials—to producing an early detection test for ovarian cancer that could one day become part of a woman’s standard annual health check-up.

The OCRF’s goal is to create a world where every woman, everywhere is free from the threat of ovarian cancer, and your tax-deductible gift will help the OCRF achieve an important step in the journey. We ask you to help us raise $45,000 to continue funding this valuable project at the level required. Click here to donate now.

Every woman who has been diagnosed, or watched a loved one endure treatment, knows that an early detection test is essential for reducing the alarmingly high mortality rate of ovarian cancer. Because without an early detection test, five-year survival rates are as low as 30%. Just as worryingly, close to 90% of women diagnosed with ovarian cancer experience recurrence within 18 months.



At her usual gynaecological check-up in April last year, Leane mentioned several symptoms she had noticed—cramps, bloating, and needing to urinate more frequently. No one would have guessed that Leane had stage 3C ovarian cancer—it was a shock discovery following an ultrasound ordered to confirm a diagnosis of menopause.

“In hindsight, I think about how I could have done something sooner. I think about how I could have known. But that’s the worrying part—without an early detection test, we don’t have a reliable way of knowing early.”

Despite initial positive results following immediate surgery, Leane is currently receiving treatment due to a recurrence detected in March.



Why is an early detection test proving so elusive? It’s the question that women, loved ones and researchers alike grapple with, and something that we at the OCRF are determined to resolve.

Despite the difficulties involved with studying a disease which has over 20 subtypes, each occuring differently, with unique rates of spread and treatment efficacy, ovarian cancer research has made some significant strides in the past decade. Thanks to this ongoing work, researchers are now confident of where they need to hone their research efforts, driving us closer to finding the solution.

In addition to finding an early detection test, OCRF-funded researchers are investigating projects that aim to improve personalised therapeutics and treatment methods for individuals, as well as considering treatment and prevention of ovarian cancer recurrence.



The OCRF-funded project, ‘Measuring the CXCL10 Active Ratio‘ is currently investigating a protein biomarker capable of providing an early stage indicator of ovarian cancer. This study has made exciting progress and is now at the stage of prospective trial, which will be conducted with women who are genetically at risk of developing ovarian cancer.

The next challenges involve refining the test to ensure that it works at the highest degree of specificity and sensitivity—minimising the chances of false positives, while ensuring no malignant tumours go undetected.

The goal is to continue testing to improve this method, until one day soon, the Active Ratio Test forms a part of a woman’s standard health check-up and screening schedule.



This is a promising time for ovarian cancer research, and this progress would not have been possible without years of ongoing funding from the OCRF.

Please make a tax-deductible gift to part fund an additional researcher to continue this life-saving research.

Research is the only way that we will find an early detection test for ovarian cancer—the key to saving Australian women’s lives and creating a future free from the fear of this insidious disease. And it is only thanks to ongoing support that we can continue to fund this life-saving work.

Please give generously to support this vital research.